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ABSTRACT
Nanosized vesicles are considered key players in cell to cell communication, thus 
influencing physiological and pathological processes, including cancer. Nanovesicles 
have also been found in edible-plants and have shown therapeutic activity in 
inflammatory bowel diseases; however information on their role in affecting cancer 
progression is missing.
Our study identify for the first time a fraction of vesicles from lemon juice (Citrus 
limon L.), obtained as a result of different ultracentrifugation, with density ranging 
from 1,15 to 1,19 g/ml and specific proteomic profile. By using an in vitro approach, 
we show that isolated nanovesicles inhibit cancer cell proliferation in different 
tumor cell lines, by activating a TRAIL- mediated apoptotic cell death. Furthermore, 
we demonstrate that lemon nanovesicles suppress CML tumor growth in vivo by 
specifically reaching tumor site and by activating TRAIL-mediated apoptotic cell 
processes. Overall, this study suggests the possible use of plant-edible nanovesicles 
as a feasible approach in cancer treatment.
INTRODUCTION
Physiological cell to cell communication occurs in 
order to maintain tissue homeostasis. Among the different 
mechanisms that have been described in the past years, 
extracellular vesicle-mediated cell interaction has attracted 
recently the interest of researchers because of the ability 
of these vesicles to shuttle a variety of molecules from 
the producing cell to target cells [1]. Extracellular vesicles 
(EVs) are membranous vesicles of different size (30–1000 
nm), released by a variety of cell types. Among the EVs 
different types, exosomes are nanometer sized vesicles 
(30–100 nm) present in biological fluids of different 
organisms. They carry various molecular constituents of 
the producing cell, including proteins, lipids, mRNAs, 
and microRNAs (miRNAs) [1]. An increasing number 
of evidences have demonstrated that exosomes exert 
an important role in cell-to-cell communication and 
influence both physiological and pathological processes, 
such as cancer and neurodegenerative disorders [1–4]. 
Additionally, molecular constituents in exosomes have 
been found to be associated with certain diseases and 
treatment responses, indicating that they may also serve 
as a diagnostic tool [5].
Previous studies suggested that nanosized particles 
from plant cells may be exosome-like [6]. Zhang and 
colleagues have reported that nanoparticles derived 
from edible plants (grape, grapefruit, ginger and carrots) 
show anti-inflammatory properties in inflammatory 
bowel diseases [7, 8]. Although it has been shown that 
compounds and/or aqueous extracts from different plant 
varieties exert anti-proliferative and anticancer activity 
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[9–12], the specific role of plant-derived nanovesicles to 
influence cancer progression is still unknown.
The tumor necrosis factor (TNF)-related apoptosis-
inducing ligand- receptor (TRAIL-R) family has emerged 
as a key mediator of cell fate and survival, by initiating 
the extrinsic apoptotic pathway [13]. Importantly, unlike 
many chemotherapeutic drugs, TRAIL has the ability to 
induce apoptosis in transformed but not in normal cells, 
thus being considered of great therapeutic potential [14, 
15]. In addition, most cancer cells can be sensitized for 
TRAIL-induced apoptosis [16].
Here, we show that the juice of Citrus Limon L. (family 
Rutaceae) contains nanoparticles, with morphological, 
dimensional and proteomic profile that allowed us to consider 
them as exosome-like nanovesicles. We found that isolated 
nanovesicles have in vitro antineoplastic activity on a panel of 
different solid and hematological cancers cell lines. Strikingly, 
we demonstrated that lemon-derived nanovesicles have 
also an effect in vivo, by suppressing the growth of a CML 
xenograft model. Moreover, we showed that lemon- derived 
nanoparticles exert their anticancer activity, by stimulating a 
TRAIL-mediated apoptotic mechanism.
All together, these findings highlight an alternative 
approach for cancer treatment, focused on using 
nanoparticles from natural substances, thus suggesting that 
the combination of natural agents and chemotherapy could 
be in the next future a feasible approach to eradicate cancer.
RESULTS
Isolation and characterization of 
Citrus limon L.-derived nanovesicles
Citrus limon L. nanovesicles were isolated 
from the fruit juice using ultracentrifugation method 
and purification on a 30% sucrose gradient. Electron 
microscope analysis showed the integrity and size of 
isolated vesicles, ranged between 50–70 nm (Figure 1A). 
Nanovesicle size distribution was also confirmed by 
dynamic light scattering (DLS) experiments as shown 
in Figure 1B. Taken together, our data showed that 
nanovesicles identified in Citrus limon are exosome-like, 
based on their morphology and size.
Proteome profiling of Citrus limon juice L.-derived 
nanovesicles
Citrus limon is a nonmodel plant species and due to 
the lack of complete genomic sequences and proteomic 
data, the availability of protein sequences in commonly 
employed databases is limited. Thus, to obtain maximum 
proteome coverage, it is usually suggested to perform 
a homology search by employing multiple databases. 
However, this strategy may determine a large number 
of identifications that generally are highly redundant 
and need to be checked, greatly affecting proteomic 
characterization and hindering a comprehensive and 
reliable protein identification. We therefore performed our 
search against a restricted protein database, namely Citrus 
database, which comprises 39096 entries (July 2014). 
By merging the results of GeLC-MS/MS and LC-MS/
MS analyses, we confidently identified 580 proteins with 
a FDR of less than 1%. However, although confidently 
identified, many proteins were still uncharacterized from 
a functional point of view. In order to attribute a molecular 
function also to the “uncharacterized proteins”, we looked 
for all of identified proteins in KEGG ORTHOLOGY 
(KO) database that collects functionally identical genes 
(orthologs). The list of total proteins identified in Citrus 
nanoparticles is provided in Supplementary Table S1. 
In this table, for each identified protein we reported the 
results obtained by searching in both Citrus and KO 
databases, and numbers and sequences of corresponding 
peptides used for the identification. Finally, by comparing 
the Citrus-derived nanovesicles protein dataset with 
the exosome protein one reported in ExoCarta database 
(4563 entries), we found that 56.7% of proteins of our 
dataset overlapped with those previously identified as 
exosome proteins in mammalian tissues and cell types and 
belonging to functional groups that characterize exosomes 
regardless of their cellular origin (Figure 1C) [17].
Citrus limon L.-derived nanovesicles are 
internalized and reduce the viability of 
cancer cells
In order to determine if Citrus nanovesicles are 
internalized by human cancer cells, nanovesicles were 
labeled with the lipophilic dye PKH26. The human 
lung carcinoma cell line A549 and the chronic myeloid 
leukemia cell line LAMA84 cells treated at 37°C with 
20 μg/ml of nanovesicles for 3 or 6 h internalized lemon 
nanovesicles in a time dependent manner as shown in 
Figure 1D (left and right panel); the uptake was impaired 
after incubation at 4°C (Supplementary Figure 1A), thus 
confirming that nanovesicles uptake was mediated by a 
biologically active process.
In order to test the ability of Citrus-derived 
nanovesicles to influence the growth of tumor cells, 
A549, SW480 (human colorectal adenocarcinoma cell 
line) and LAMA84 cells were treated for 24, 48 or 72 h 
with 5 or 20 μg/ml of nanovesicles. The MTT viability 
assay showed that lemon nanovesicles inhibited tumor cell 
viability in a dose and time dependent manner compared 
with untreated cells (Figure 2A upper panel). The results 
herein showed a 50% growth reduction of the three cell 
lines with 20 μg/ml of nanovesicles at 48 h time point. 
In order to assess the specificity of lemon nanovesicles 
against tumor cell lines, non-cancer cell lines HS5 (Human 
bone marrow stromal cells), HUVEC (Human Umbilical 
Vein Endothelial Cells) and PBMC (Human peripheral 
blood mononuclear cells) were treated according to the 
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same experimental conditions. As shown in the lower 
panel of Figure 2A, citrus nanovesicles did not affect the 
growth of normal cells. In addition, we found that the 
effects observed on cancer cell proliferation depended on 
nanovesicles integrity and stability, as their destruction, by 
boiling or sonication leads to the disappearance of the anti-
proliferative effects (Supplementary Figure 1B).
To better evaluate the ability of Citrus nanovesicles 
to inhibit in vitro tumor growth, we performed a colony 
formation assay in methylcellulose. As shown in Figure 2B, 
A549, SW480 and LAMA84 cells treated with different 
concentration of nanovesicles formed a lower number of 
colonies when compared to untreated control cells.
The results reported herein showed that Citrus 
nanovesicles were active against the tumor cell lines 
A549, SW480 and LAMA84, while they did not affect 
the proliferation of normal cells, thus confirming the 
specificity of their effect towards cancer cells.
Citrus nanovesicles activate the expression of 
pro-apoptotic molecules
To evaluate the mechanism by which Citrus 
nanovesicles were able to suppress tumor growth, we 
tested the expression of different molecules involved in 
the apoptotic pathway. As shown in Figure 3A, A549, 
SW480 and LAMA84 cells treated for 24 or 48 hours 
with lemon nanovesicles showed an increased expression 
of the pro-apoptotic genes, Bad and Bax, and a reduction 
of the anti-apoptotic genes Survivin and Bcl-xl, in 
particular after 48 h of treatment. The increase of BAX 
protein expression (4.5-fold increase in A549, 1.65-fold in 
Figure 1: Nanovesicles characterization and uptake by target cells. A. Citrus nanovesicles were collected after 30% sucrose 
gradient ultracentrifugation and analyzed at transmission electron microscope. The scale bar indicates 200 nm. B. Nanovesicles size 
distribution was determined by DLS analysis. C. The Venn diagram shows a comparison between the Citrus nanovesicle data set and protein 
ExoCarta data set. The overlapping area contains about 60% of proteins identified in Citrus nanovesicles. Most of these common proteins 
belong to functional groups highly associated with exosomes. D. Analysis at confocal microscopy of A549 (left panel) or LAMA84 cells 
(right panel) treated, for 3 and 6 hours, with 20 μg/ml of Citrus nanovesicles, compared with untreated cells (Ctrl). Cells were stained with 
Actin Green 488 (green), nuclear counterstaining was performed using Hoechst (blue), nanovesicles were labeled with PKH26 (red).
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SW480, 3.6-fold in LAMA84) and the decrease of BCL-
xL (0.7-fold decrease in A549, 0.88-fold in SW480, 0.82-
fold in LAMA84), were also confirmed by western blot 
analysis (Figure 3B).
Citrus nanovesicles induce TRAIL-mediated 
cell death
Several studies showed that many natural products 
exhibited antineoplastic activities related to tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) signaling. TRAIL activation has been shown 
to induce apoptosis in tumor cells while has minimal 
toxicity against normal tissues [18]. Therefore, to 
further explore the apoptotic mechanism induced by 
Citrus nanovesicles, we measured the expression of 
Trail and its receptor Dr5 that tightly control apoptotic 
processes.
We found that nanovesicles treatment of cancer 
cell lines induced an upregulation of Trail (Figure 4A, 
upper panel) and Dr5 (Figure 4A, lower panel) mRNA 
levels, with a significant increase after 48 h. As expected, 
no changes in Trail mRNA expression levels in normal 
cell line HS5 treated with nanovesicles (Supplementary 
Figure 1C) were observed. The increased release of 
TRAIL protein was also confirmed by ELISA assays 
as shown in Figure 4B. To note, the increase of TRAIL 
protein level was higher in the CML cell line, LAMA84.
To further demonstrate that the observed 
nanovesicles-induced cell death was activated through 
the TRAIL/DR5 pathway, we used human TRAIL 
neutralizing antibodies. As shown in Figure 4C the 
co-treatment of cancer cells with Citrus juice-derived 
nanovesicles and TRAIL neutralizing antibody 
significantly reverted the effects of nanovesicles on 
tumor cell death. To further investigate if the decrease 
in cell growth observed after nanovesicles treatment was 
due to the activation of TRAIL-stimulated apoptotic cell 
death, Annexin V–FITC fluorescence was measured by 
flow cytometry on cancer cell lines treated for 48 h with 
Figure 2: Citrus nanovesicles inhibit the growth of tumor cell lines. A. Cell growth was measured by MTT assay after 24, 48, 
72 h of treatment with 5 or 20 μg/ml of nanovesicles. The values were plotted as absorbance. Each point represents the mean ± SD of 
three independent experiments. B. Cancer cell survival was assessed by colony formation assay in methylcellulose. Cells were plated in 
methylcellulose in presence or not of 5 and 20 μg/ml of Citrus nanovesicles. The values were plotted as fold change compared to control 
cells (untreated cells). Each point in the histogram represents the mean ± SD of three independent experiments. Asterisks indicate statistically 
significant values in comparison to control (Ctrl) (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). Pictures are representative of observed colonies.
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20 μg/ml of lemon nanovesicles in presence or absence 
of TRAIL neutralizing antibodies. Figure 4D showed 
an increase of apoptotic cell death in all the cell lines 
treated with nanovesicles (up to 15% in A549, 19% in 
SW480, 24% in LAMA84), while blocking TRAIL led 
to a reversion of these effects. Overall our data confirmed 
that lemon-derived nanovesicles stimulated cancer cell 
death by activating TRAIL-mediated apoptosis.
Citrus nanovesicles reduce the growth 
of CML xenografts
The ability of Citrus nanovesicles to reduce tumor 
growth was also tested in an in vivo tumor xenograft 
model. LAMA84 cells were inoculated subcutaneously in 
NOD/SCID mice; one week post cell injection, mice were 
treated locally (intra tumor, IT) or intraperitoneally (IP) 
three times a week with vehicle (PBS) or lemon- derived 
nanovesicles. At the end of treatment regime, mice were 
sacrificed and the tumors removed. Strikingly, in Figure 5A 
we showed that tumor growth was reduced in mice treated 
with Citrus nanovesicles, both locally and intraperitoneally 
(left panel), leading to the formation of smaller tumors 
compared with control mice (right panel). There are 
no statistically significant differences between the two 
different groups of mice treated with nanovesicles.
In order to confirm our in vitro data, we tested whether 
in vivo tumor size reduction was stimulated by TRAIL 
Figure 3: Citrus nanovesicles affect the balance between pro- and anti-apoptotic molecules. A. Real-time PCR analysis 
was performed on A549, SW480 and LAMA84 cell lines treated for 24 or 48 hours with 5 or 20 μg/ml of nanovesicles to evaluate mRNA 
levels of the pro-apoptotic and anti-apoptotic genes. The values were plotted as fold change compared to control (untreated cells). Each 
point represents the mean ± SD of three independent experiments. Asterisks indicate statistically significant values in comparison to control 
(Ctrl) (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). B. Western blot analysis was performed on cells treated for 48 h with 20 μg/ml of Citrus 
nanovesicles. Protein levels of the pro-apoptotic (BAX) and anti-apoptotic (BCL-xL) were evaluated. Blots were stripped and subsequently 
re-probed with an antibody against β-actin to ensure equal loading. Histograms represent densitometry analysis of protein levels in treated 
cells (Nanoves) versus untreated cells (Ctrl). Each point represents the mean ± SD of three independent experiments.
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activation. Real-time PCR analysis of the mRNAs isolated 
from in vivo xenograft tumors showed an increase of Trail 
and Dr5 mRNA. In addition, we found that nanovesicle 
administration led to an increase of the pro-apoptotic 
gene Bax in nanovesicle-treated mice concomitantly to a 
decrease of the anti-apoptotic genes Survivin and Bcl-xl 
(Figure 5B); to note, the differences in the expression of 
Trail and its receptor were strongest in xenografts from mice 
treated locally. Furthermore, our results were confirmed 
by immunofluorescence analysis of TRAIL; we found an 
increased number of TRAIL positive cells in the tumors of 
mice treated locally or intraperitoneally with nanovesicles 
when compared with control mice (Figure 5C).
To further investigate other mechanisms that might 
be involved in nanovesicle-dependent tumor inhibition, we 
performed a multiplex cytokine analysis and we found that 
the administration of nanovesicles led to the decrease of 
the pro-angiogenic factors, such as VEGF-A, IL6 and IL8 
in the serum of treated-mice compared with untreated ones 
(Figure 5D, upper panel). To note, the reduction of these 
Figure 4: Citrus nanovesicles induce TRAIL-mediated cell death. A. Real-time PCR analysis was performed on A549, SW480 and 
LAMA84 cell lines treated for 24 or 48 hours with 5 or 20 μg/ml of Citrus nanovesicles to evaluate mRNA levels of Trail and Dr5. The values 
were plotted as fold change compared to control (untreated cells). Each point represents the mean ± SD of three independent experiments. 
B. ELISA was performed to determine TRAIL concentration in the conditioned medium of A549, SW480 and LAMA84 cell lines treated for 
24 or 48 hours with 5 or 20 μg/ml of Citrus nanovesicles. The values are expressed in ng/ml. Each point represents the mean ± SD of three 
independent experiments. Asterisks indicate statistically significant values in comparison to control (Ctrl). C. Cell growth was measured by MTT 
assay after 48 h of treatment with 20 μg/ml of nanovesicles in presence or not of 5 or 20 ng/ml of neutralizing anti TRAIL antibodies. The values 
were plotted as % of growth vs control (untreated cells). Each point represents the mean ± SD of three independent experiments. D. Cell death 
was detected by Annexin V staining after 48 h of treatment with 20 μg/ml of Citrus nanovesicles in presence or not of 20 ng/ml of neutralizing 
anti TRAIL antibodies. Figure shows representative overlay histogram from untreated cells (solid line), cells treated with nanovesicles (dashed 
line) or with nanovesicles and neutralizing anti TRAIL antibodies (dotted line). Histogram reported % of Annexin V positive cells in samples 
treated compared to untreated (Ctrl). Asterisks indicate statistically significant differences (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).
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factors is more significant in locally treated mice (IT). The 
downregulation of VEGF-A, together with the decrease 
of its receptor, was also validated by Real time PCR in 
the xenograft tumors, as shown in Figure 5D, lower 
panel. Interestingly, we found a comparable decrease 
of the same pro-angiogenic factors in the conditioned 
medium of LAMA84 cell line treated with nanovesicles 
(Supplementary Figure 2).
All together, these data suggested that Citrus limon 
nanovesicles are able to reduce in vivo tumor growth 
by TRAIL-mediated apoptosis and by inhibition of the 
secretion of cytokines involved in angiogenesis.
In vivo distribution of Citrus nanovesicles
In order to test Citrus nanovesicle in vivo 
distribution, nanoparticles were labeled with the 
lipophilic fluorescent tracer DiR (1, 10-dioctadecyl-3, 3, 
30, 30-tetramethylindotricarbocyanine). As reported in 
Figure 6A, Nanovesicles- DiR, ranging from 5 to 50 μg 
of vesicles, showed a fluorescence signal that correlated 
linearly with nanovesicles concentration.
To assess if nanovesicles inhibited tumor growth 
by reaching tumor site, NOD/SCID mice were treated 
intraperitoneally with Citrus nanovesicles labeled with the 
Figure 5: Citrus nanovesicles inhibit in vivo tumor growth. A. LAMA84 cells were injected subcutaneously in NOD/SCID 
mice as described. After palpable tumor formation, mice were treated as described in Materials and Methods. Comparison of the median 
tumor weight was used as an index of the antitumor efficacy of Citrus nanovesicles. Asterisks indicate statistically significant values in 
comparison to control (Ctrl) (***p ≤ 0.001) B. mRNA levels of pro- , anti-apoptotic genes, Trail and Dr5 were evaluated in samples from 
mice xenografts. The values were plotted as fold change compared to xenograft control. Each point represents the mean ± SD for three 
independent experiments. Asterisks indicate statistically significant values in comparison to control (Ctrl) (**p ≤ 0.01; ***p ≤ 0.001). 
C. Representative images of confocal fluorescence microscopy show TRAIL (green) immunolabeling in paraffin sections from xenografts. 
Nuclear counterstaining was performed using Hoescht (blue). Arrows indicate TRAIL positive cells. D. Multiplex cytokine evaluation of 
VEGF-A, IL6 and IL8 in the serum of mice treated or not with nanovesicles. The values are expressed in pg/ml (upper panel). mRNA levels 
of Vegf-A and Vegf-A receptor were evaluated in samples from mice xenografts (lower panel). The values were plotted as fold change 
compared to control. Each point represents the mean ± SD for three independent experiments. Asterisks indicate statistically significant 
values in comparison to control (Ctrl) (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).
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lipophilic fluorescent tracer DiR, with Free-DiR, or with 
PBS, one week after subcutaneously injection of CML cells. 
Mice were imaged using an IVIS Optical Imaging System 
at 15 minutes, 1 and 24 h post injection. At the 24-hour time 
point, mice were sacrificed and organs excised. As shown in 
Figure 6B and Supplementary Figure 3A, labeled nanovesicles 
(Nanovesicles-DiR) quickly reached tumor tissue and 
accumulated starting at 15 minutes, 1 h and up to 24 hour time 
point, while the Free-DiR never reached the tumor site.
Analysis of organs excised 24h post injection 
showed that both Free-DiR and Nanovesicles-Dir are 
significantly taken up by liver, spleen and partially by 
kidneys (Figure 6C and Supplementary Figure 3B). A 
similar distribution of both Free-DiR and Nanovesicles-
Dir were observed in organs excised from healthy mice 
(Supplementary Figure 3C). Analysis of tumors (from 
mice injected with Free-DiR or with Nanovesicles-DiR) 
indicates that nanovesicles are internalized by tumors and 
remain in the tumor mass, while no signal accumulation 
was observed in the tumors from mice treated with the 
probe alone (Free-DiR) (Figure 6C).
Taken together, these results clearly suggest the 
specificity of nanovesicles to reach tumor sites in vivo.
DISCUSSION
Currently, many natural compounds emerged as 
alternative strategies for cancer prevention and therapy 
[19]. Natural compounds are used in monotherapy or in 
association with chemotherapeutic drugs, thus allowing the 
use of lower dosage of chemotherapeutic agent in order to 
overcome drug resistance and toxicity on normal tissues.
Numerous data in literature showed that Citrus fruit, 
commonly used in traditional medicine in China and other 
Figure 6: In vivo Citrus nanovesicles biodistribution. A. Representative in vitro fluorescence images of DiR-labeled Citrus 
nanovesicles dilutions from 50 to 5 μg of nanovesicles in 150 μl of PBS; the quantification of fluorescence signal was calculated in the entire 
area of each well through the use of ROIs. Data are expressed as average radiance efficiency ([p/s/cm2/steradian]/[μW/cm2]). B. NOD/
SCID mice bearing CML xenograft tumors in the right flank were injected intraperitoneally with PBS, Free-DiR, 50 μg Nanovesicles-DiR 
in a volume of 150 μl PBS. Mice were imaged at 15 min, 1 h and 24 h post injection. A scale of the radiance efficiency is presented to the 
right of each live mouse image. C. Organs and tumors were excised and imaged after 24 h. A scale of the radiance efficiency is presented 
to the right. Histogram represents ex vivo quantification of tumor fluorescence.
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countries, has an anti-proliferative effect in many types 
of cancers [20, 21]; however, it is still unknown how this 
occurs and through which molecular mechanisms.
Evidences support the occurrence of multivesicular 
bodies-mediated secretion of exosome-like vesicles 
in plants [6], but the understanding of their functional 
role in cross-kingdom interaction requires further 
exploration. Zhang and colleagues have reported that 
grape nanoparticles are taken up by mouse intestinal 
macrophages, thus inducing the expression of anti-oxidant 
genes and suppressing the production of pro-inflammatory 
cytokines [7]. However, the role of plant-nanovesicles to 
influence cancer progression has never been described.
Our findings showed that we were able to isolate 
a homogeneous population of nanovesicles from Citrus 
limon-juice, with dimension, morphology and protein 
contents attributable to exosome-like nanoparticles 
[17]. Furthermore, we showed that these nanovesicles 
are stable and with a functional role in cross-kingdom 
communication. In particular, for the first time, we 
showed that they inhibit cancer cell growth without 
affecting normal cells. The mechanism of action of many 
anticancer compounds is based on their ability to induce 
apoptosis. Many natural products exert their apoptotic 
effects by inducing TRAIL-mediated cell death [22, 23]. 
It has been largely described that TRAIL selectively 
induces apoptosis of cancer cells without affecting normal 
cells [16, 24, 25]. Furthermore, it has been described that 
many types of tumor are TRAIL-resistant due to the low 
expression levels of TRAIL receptors [26]. Therefore, the 
development of agents that can sensitize cells to TRAIL-
mediated cell death are needed. Here we showed that 
the treatment of lung, colon and leukemia cancer cells 
with Citrus nanovesicles affects pro-and anti-apoptotic 
pathways, leading to the increase in the mRNA levels of 
the pro-apoptotic molecules Bad and Bax, together with 
the decrease of pro-survival molecules, such as Survivin 
and Bcl-xl. Furthermore, we observed an increased 
expression of TRAIL-receptor, Dr5, in cancer cell lines 
treated with nanovesicles, together with the increase and 
release of TRAIL, thus hypothesizing an autocrine loop 
induced by lemon vesicles that leads to cancer cell death.
To validate our in vitro findings showing the pro-
apoptotic effects of nanovesicles on tumor cell lines, 
we used an in vivo xenograft model of chronic myeloid 
leukemia (CML). Data reported here showed that the 
administration of Citrus nanovesicles strongly suppressed 
tumor growth and we confirmed, in vivo, that this effect was 
due not only to TRAIL-mediated apoptosis but also to the 
inhibition of angiogenic processes, as shown by the reduced 
levels of pro-angiogenic cytokines VEGF-A, IL6 and IL8. 
Interestingly, our data are consistent with our previous 
results demonstrating the ability of exosomes-induced 
IL8 to stimulate CML cell proliferation and survival [27]. 
Moreover, through in vivo optical imaging analysis we 
proved that nanovesicles exert these effects by reaching 
tumor site. Overall, our data showed that the pro-apoptotic 
effects of Citrus limon may be attributed to structural 
components and in particular to exosomes-like nanovesicles. 
Furthermore, the possible mechanism by which nanovesicles 
exert the in vitro and in vivo antineoplastic activity involves 
TRAIL-mediated pathways as well as angiogenic inhibition.
In summary, we have identified for the first time 
nanovesicles from Citrus limon juice with antineoplastic 
potential. Our findings open to the possibility to develop 
new anticancer strategies based on the use of plant-edible 
nanovesicles.
MATERIALS AND METHODS
Ethics statement
All animal experiments were conducted in full 
compliance with University of Palermo and Italian 
Legislation for Animal Care. The Dipartimento di 
Biopatologia e Biotecnologie Mediche (DiBiMed) Review 
Board approved this study.
Cell culture and reagents
The human chronic myeloid leukemia cell line, 
LAMA84, was obtained by DSMZ (Braunschweig, 
Germany). The human colorectal adenocarcinoma cell 
line, SW480, the human lung carcinoma cell line, A549, 
and the human bone marrow-derived stromal cell line, 
HS5, were obtained by ATCC (Manassas, VA, USA). 
LAMA84, SW480 and A549 cell lines were cultured in 
RPMI 1640 medium (Euroclone, UK), HS5 (Human bone 
marrow stromal cells) cell line was cultured in DMEM 
high glucose (Euroclone, UK). Human Umbilical Vein 
Endothelial Cells (HUVEC) were obtained from Lonza 
and grown in Endothelial Growth Medium (EGM, 
Clonetics, Verviers, Belgium). Human peripheral blood 
mononuclear cells (PBMC) were isolated using Ficoll 
Paque (GE Helthcare Bio Science, Uppsala, Sweden). 
Anti-TRAIL neutralizing antibody was from AbCam 
(Cambridge, UK). All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), if not cited 
otherwise.
Nanovesicles preparation
Nanovesicles were isolated from Citrus limon L. 
juice. Fruits, obtained from a private farmer, were carefully 
washed in water and manually squeezed. The juice was 
sequentially centrifuged at 3,000 × g for 30 minutes, and 
10,000 × g for 1 hour. The supernatant was filtered at 
0.8 μm and 0.45 μm pore filter and centrifuged at 16,500 × g 
for 3 hours. The supernatant was then centrifuged at 
120,000 × g for 90 minutes in a Type 70 Ti, fixed angle rotor, 
the pellet was suspended in 1 ml PBS and transferred to a 
30% sucrose/D2O cushion. Vesicles contained in the cushion 
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were recovered, washed several times, ultracentrifuged 
for 90 min in PBS and collected for use. Nanovesicles 
quantification was determined with the Bradford assay 
(Pierce, Rockford, IL, USA). On average, we recovered 600 
micrograms of vesicles from 240 ml of Citrus juice.
Dinamic light scatter (DLS)
Nanovesicles size distribution was determined by 
dynamic light scattering (DLS) experiments. Collected 
nanovesicle samples were diluted to avoid inter-particle 
interaction and placed at 20°C in a thermostatic cell 
compartment of a Brookhaven Instruments BI200-SM 
goniometer, equipped with a solid-state laser tuned at 
532 nm. Scattered intensity autocorrelation functions were 
measured by using a Brookhaven BI-9000 correlator and 
analyzed in order to determine the size distribution [28]. 
The size at the maximum of the distribution (moda) is 
reported as a significant average size.
Transmission electron microscopy (TEM)
Nanovesicles resuspended in PBS (10μg) 
were spotted onto carbon-coated grids, fixed in 1% 
glutaraldehyde and stained in 2% phosphotungstic acid. 
The preparation obtained was examined immediately 
using a JEOL JEM-1400 Plus transmission electron 
microscope, at 110 kV.
Sample preparation for proteomic analysis
Gel-free and gel-based protein fractionation 
procedures were employed and combined with LC-MS/
MS analysis in order to increase the proteome coverage of 
Citrus limon nanovesicles.
In gel-free approach nanoparticles isolated from 
Citrus limon juice were processed using 50% 2,2,2- 
trifluoroethanol (TFE) in PBS and incubated with constant 
shaking for 1 h at 60°C. Reduction was performed with 
5 mM dithiothreitol (DTT) for 30′ at 60°C and alkylation 
with 25 mM iodoacetamide (IAA) for 30′ in the dark 
at room temperature. Prior to trypsin addition, sample 
was diluted with four-volumes of 100 mM NH4HCO3 
pH 8.0. Proteins were digested overnight at 37°C using 
sequencing-grade modified porcine trypsin (Pierce). After 
overnight incubation, digestion was stopped by adding 
20 ul of 90% FA and peptide mixture centrifuged at 
14000g for 10′ at 4°C.
In the gel-based approach (GeLC-MS/MS), nano-
vesicle proteins extracted as previously described [29] 
were separated by 10% SDS-PAGE and stained with 
colloidal Coomassie Blue solution. Gel lane was cut into 
eight gel slices of similar size and further cut into about 
1 mm3 particles; in-gel digestion protocol was adapted 
from Shevcenko et al. [30]. Peptides obtained from the 
two procedures were finally dried down with a speed 
vacuum centrifuge and desalted by solid phase extraction 
using C18 Macrospin Columns.
Liquid chromatography-tandem mass 
spectrometry
The MS analysis was performed using a Triple 
TOF 5600 Plus System (AB Sciex, Framingham, U.S.A.) 
equipped with an Eksigent Nanoflow binary gradient 
HPLC system and a nanospray III ion source. Two 
microliters of sample were injected on a reversed-phase 
trap column for peptide cleanup and pre-concentration, 
employing a mobile phase, from loading pump, 
containing 0.1% v/v FA in water at a flow rate of 5 ul/
min. Peptides were then eluted onto the C18 analytical 
column, equilibrated at 40°C with a solvent A (0, 1% FA 
in water) at a flow rate of 250 nL/min, and separated using 
a gradient method according to which solvent B (0, 1% FA 
in acetonitrile) was linearly increased from 10% to 28% 
within 60 min and then to 60% within 15 min; afterwards, 
phase B was further increased to 95% within 1 min. Then, 
phase B was maintained at 95% for 5 min to rinse the 
column. Finally, B was lowered to 10% over 1 min and the 
column reequilibrated for 18 min (100 min total run time).
The eluting peptides were on-line sprayed in 
the Triple TOF 5600 Plus mass spectrometer, that it 
is controlled by Analysts 1.6.1 software (AB SCIEX, 
Toronto, Canada).
Data were acquired using an ion spray voltage of 
2.7 kV, curtain gas set at 35, GS1 1 and GS2 0 PSI nitrogen 
flow, source temperature 80°C. MS/MS spectra were 
collected using Information Dependent Acquisition (IDA); 
precursor ions were selected across the mass range of 350 
to 1250 m/z in high resolution mode (>30, 000) using 250 
ms accumulation time per spectrum. A maximum of 35 
precursors per cycle from each MS spectrum, with charge 
state from 2 to 5, were selected for fragmentation, if 
exceeding a threshold of 70 counts per second (cps), with 
100 ms minimum accumulation time for each precursor 
and dynamic exclusion for 15 s. Tandem mass spectra were 
recorded in high sensitivity mode (resolution > 15,000) 
with rolling collision energy.
Protein identification and data analysis
Raw MS/MS data files from Analysts 1.6 software 
were submitted to ProteinPilot™ 4.5 software (AB 
SCIEX, Toronto, Canada), using the Paragon Algorithm 
and Uniprot’s Citrus database (39096 entries, July 
2014); For all analyses, the search was performed with 
the following settings: (1) Sample Type: identification; 
(2) Cysteine Alkylation: Iodocetamide; (3) Digestion: 
Trypsin; (4) Instrument: TripleTOF 5600; (5) Special 
factors: /Gel-based ID (for samples from GeLC-MS/
MS analysis) /None (for samples from LC-MS/MS); (6) 
Species: None; (7) Search Effort: Thorough ID; (8) FDR 
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Analysis: Yes. Moreover, further analysis were performed 
with the KEGG Orthology (KO) system (http://www.
genome.jp/kegg/ko.html) and the exosome database 
ExoCarta (http://exocarta.org) [31].
Uptake of Citrus nanovesicles by A549 and 
LAMA84 cells
Citrus nanovesicles were isolated as described 
above and labeled with PKH26 (Sigma-Aldrich, St. 
Louis, MO, USA) for 10 min at room temperature. 
Labeled nanovesicles were washed twice in PBS and 
resuspended in complete medium. A549 and LAMA84 
cells were grown on coverslips coated with type I collagen 
(Calbiochem, Darmstadt, Germany) and treated with 20 
μg/ml of labeled vesicles for 3 or 6 hours at 4°C or 37°C. 
Cells were stained with Actin Green 488 (Molecular 
probes, Life Technologies, California, USA). Nuclei 
were stained with Hoechst 3342 (Molecular probes, Life 
Technologies) and analysed by confocal microscopy.
Viability assay (MTT assay)
Cell viability was assessed with Methyl-thiazol-
tetrazolium (MTT) assay as previously described [32]. 
Briefly, cells were seeded at a density of 0.1 × 106 in a 
96-well plate and exposed to escalating doses of Citrus 
nanovescicles (5–20 μg/ml) for 24, 48 or 72 hours, and in 
the presence or not of 5, 20 μg/ml of neutralizing TRAIL 
ab. MTT assay was also performed on A549 cell line 
treated for 24, 48 or 72 hours with 5 or 20 μg/ml of boiled 
or sonicated nanovesicles. The absorbance was measured 
at 540 nm. Means and standard deviations generated 
from three independent experiments are reported as the 
percentage of growth versus control (untreated cells). Cell 
proliferation curves were derived from these data with 
Microsoft Excel software.
Colony formation assay
A549, SW480 and LAMA84 cells were plated in 
6-well (2000 cells/ml/well) in Iscove’s-methylcellulose 
medium (Methocult H4230, Stem Cell Technologies, 
Vancouver, Canada) containing or not nanovesicles (5, 20 
μg/ml). After 14 days of culture, colonies were observed 
by phase-contrast microscopy and photographed. The area 
of twenty colonies per condition was measured with the 
IMAGE-J software (http://rsbweb.nih.gov/ij/).
Annexin V assay
To detect tumor cell apoptosis, an Annexin 
V-fluorescein isothiocyanate (FITC) assay was used. 
Specifically, LAMA84, SW480 and A549 cells were 
seeded into 6-well plates, cultured for 48 h and treated 
with 20 μg/ml of Citrus vesicles in the presence or not 
of neutralizing TRAIL ab (20 ng/ml). After incubation, 
cells were washed in PBS twice and apoptosis assays 
were performed as follows. Cells were resuspended in 
cold 1X Annexin V binding buffer (10x: 0.1 M Hepes 
pH 7.4; 1.4 M NaCl; 25 mM CaCl2), transferred in a 
FACS tube and mixed with 5 μl of Annexin V-FITC 
(BD-Biosciences, San Jose, CA). The cells were then 
incubated at room temperature in the dark for 15 min. 
After adding 400 μl of annexin V binding buffer, the 
samples were subjected to flow cytometry analysis to 
detect cell apoptosis levels. Cells positive for Annexin 
V-FITC, were considered to represent apoptotic cells. 
Stained cells were acquired on FACS Calibur (BD 
Biosciences San Jose, CA) and analysed using FlowJo 
software (Tree Star, Ashland OR).
RNA extraction and real-time PCR
LAMA84, A549 and SW480 cells were grown in 
12-well plates and treated with 5 or 20 μg/ml of Citrus 
vesicles for 24 or 48 hours. Tumor biopsies soon after 
removal were stored in RNAlater solution (Applied 
Biosystems, Foster City, California, USA). Each sample 
was lysed in a tissue homogenizer. RNA was extracted 
using the commercially available Illustra RNAspin 
Mini Isolation Kit (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK), according to manufacturer’s 
instructions. Total RNA was reverse-transcribed to cDNA 
using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystem). RT-QPCR was performed in 48-
well plates using the Step-One Real-Time PCR system 
(Applied Biosystem). For quantitative SYBR®Green 
realtime PCR, the following primers were used:
GAPDH (5′ATGGGGAAGGTGAAGGTCG3′, 5′G 
GGTCATTGATGGCAACAATAT3′),
Bad (5′CCGAGGAGCAGGAAGACTC’3, 5′GGT 
AGGAGCTGTGGCGACT’3),
Bax (5′CCTGTGCACCAAGGTGCCGGAACT3′, 
5′CCACCCTGGTCTTGGATCCAGCCC3′),
Survivin (5′CTCAAGGACCACCGCATCTC’3, 5′C 
AGCCTTCCAGCTCCTTGAA’3),
Bcl-xl (5′CTGAATCGGAGATGGAGACC’3, 5′TG 
GGATGTCAGGTCACTGAA’3),
Trail (5′GCTCTGGGCCGCAAAAT’3, 5′ TGCAAG 
TTGCTCAGGAATGAA’3),
Dr5 (5′ GGGCCACAGGGACACCTT ’3, 5′ GCATC 
TCGCCCGGTTTT’3),
Vegf-A (5′ CGAGGGCCTGGAGTGTGT’3, 5′CGC 
ATAATCTGCATGGTGATG ‘3)
Vegf-A Receptor (5′ CGGTCAACAAAGTCGGGA 
GA ’3, 5′CAGTGCACCACAAAGACACG ‘3),
all obtained from Invitrogen (Foster City, CA, USA). Real-
time PCR was performed in triplicates for each data point. 
Relative changes in gene expression between control and 
treated samples were determined with the ΔΔCt method. 
Levels of the target transcript were normalized to a 
GAPDH endogenous control, constantly expressed in all 
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samples (ΔCt). For ΔΔCt values, additional subtractions 
were made between treated samples and control ΔCt 
values. Final values were expressed as fold of induction.
Western blot
A549, SW480, LAMA84 cells were treated for 
48 h with 20 μg/ml of Citrus nanovesicles. Total protein 
cell lysates were obtained and analyzed by SDS-PAGE 
followed by Western blotting. Antibodies used in the 
experiments were anti-BAX, BCL-xL and β-actin (all 
from Santa Cruz Biotechnology, CA, USA).
ELISA
A549, SW480, LAMA84 cells conditioned medium 
was collected from cells treated with 5, 20 μg/ml of Citrus 
nanovesicles for 24 or 48 h. Conditioned medium aliquots 
were centrifuged to remove cellular debris and then 
TRAIL protein concentrations were quantified using the 
ELISA kit (Uscn life Science Inc., Houston, TX, USA), 
according to manufacturer’s protocol.
CML mouse xenograft
Male NOD/ SCID mice, four-to-five weeks old, were 
purchased from Charles River (Charles River Laboratories 
International, Inc, MA, USA) and acclimated for a week prior 
to experimentation. Mice received filtered water and sterilized 
diet ad libitum. Animals were observed daily and clinical 
signs were noted. Each mouse was inoculated subcutaneously 
in the right flank with viable single human LAMA84 cells 
(2 × 107) suspended in 0.2 ml of PBS. The day of injection was 
considered as Day 0. On Day 7, when tumors were palpable, 
mice were randomly assigned to three groups of four and were 
treated with Citrus nanovesicles (50 μg/mouse, three days a 
week for two weeks) administered intraperitoneally (IP) 
or in the intratumor (IT) site or with vehicle (PBS). Tumor 
xenografts were measured and the mice were weighed three 
times a week starting on Day 7. Tumor volume was determined 
by caliper by using the following formula: L × W2/2 = mm3 
where L and W are the longest and shortest perpendicular 
measurements in millimeters, respectively. The same formula 
was used to calculate tumor weights assuming that 1 mm3 = 
1 mg. Animals were euthanized at the end of treatment, the 
tumor removed, and the tumor weights measured. Blood 
was collected by post-mortem cardiac puncture, centrifuged 
at 1500 × g for 15 min and the supernatant (serum) was 
collected and stored at –20°C. Xenografts were resuspended 
in RNA later for further RNA isolation or in 10% formalin for 
immunohistochemical analysis.
Immunofluorescence
Mice xenografts were harvested and immediately 
fixed with 10% formalin. 5-μm-thick paraffin-embedded 
tumor sections were used for Immunofluorescence. Briefly, 
slides were rehydrated and subsequently retrieved for 15 
minutes at 95°C in NaCitrate 10 mM pH 6. After antigen 
retrieval, tumor sections were permeabilized with 0.2% 
TritonX-100 in PBS for 10 minutes at room temperature and 
then blocked with Dako protein block serum free (Dako). 
Sections were incubated with mouse monoclonal antibody 
anti-TRAIL (Abcam, catalog # ab 10516) diluted 1:50 in 
blocking solution over night at 4°C. After washes in 0.2% 
TritonX-100 in PBS, sections were incubated with Alexa-
fluor 488 donkey anti-mouse (Life technologies) diluted 
1:500 in blocking solution for 1 hour at room temperature 
in the dark. Slides were subsequently counterstained with 
Hoechst 3342 and mounted for confocal analysis.
Multiplex cytokine analysis
Levels of VEGF-A, IL-6 and IL8 were determined 
in mice serum samples and in the conditioned medium of 
LAMA84 cell line using the Bio-Plex Multiple Cytokine 
Assay (Bio-Rad, Hercules, CA), according to the 
manufacturer’s instructions. Briefly 50 μL of samples and 
scalar concentrations of the assay standards were added in 
duplicates to a 96-well plate containing magnetic beads. 
The plate was incubated for 1 hour followed by washing 
steps; the plate was subsequently coated with biotinylated 
detection antibody solution and incubated for 30 minutes. 
After the 30 minutes incubation, the plate was washed and 
streptavidin-conjugated phycoerythrin was added to the 
96-well plates and incubated for 10 minutes. The plate was 
washed after this final incubation step and assay buffer 
was added to each well. Data was acquired using the 
Bio-Plex® 200 Systems. A standard curve was derived 
using the different concentrations of the assay standards. 
Data were analyzed using Bio-Plex Manager Software.
In vivo distribution of Citrus nanovesicles
Nanovesicle labeling procedure: DiR was used to 
fluorescently label the lipid bilayer of Citrus nanovesicles. 
Briefly, nanovesicles were directly labeled with 1 μM 
Vybrant Cell Tracers DiR (Life Technologies) then washed 
in PBS. To test the efficiency of DiR conjugation, 5, 10 
and 50 μg of labeled nanovesicles were in vitro evaluated 
by using a cooled charge-coupled device (CCD) camera 
imaging (IVIS Lumina; PerkinElmer LifeSciences) using the 
appropriate filter (exc = 710 nm; em = 780 nm). The same 
region of interest (ROI) was applied in the entire area of each 
well on all the fluorescent signal. Data were expressed as 
Average Radiant Efficiency [p/s/cm2/sr] / [μW/cm2].
In vivo imaging: healthy mice or mice bearing CML 
xenografts were monitored daily. Prior to nanovesicle 
injection and optical imaging acquisitions, the ventral 
hair of mice was removed. For in vivo imaging studies, 
different groups of animals were analyzed: healthy mice or 
mice bearing tumors injected with a) 150 μl PBS; b) Free 
Dir probe (1 μM in 150 μl PBS); c) 50 μg of Dir-labeled 
nanovesicles in 150 μl PBS.
Oncotarget13www.impactjournals.com/oncotarget
Briefly, for the detection of fluorescence, mice were 
anesthetized and then injected IP with PBS, Free DiR or 
DiR labeled-nanovesicles. Mice images were acquired 
after 15 minutes, 1 h or 24 h from injection. Following 
fluorescent background subtraction, images were analyzed 
and scaled after completion of all acquisitions, using 
appropriate computer software (Living Image Software; 
PerkinElmer LifeSciences). All mice were imaged with 
identical instrument settings. Following the last acquisition, 
the animals were sacrificed and the organs (spleen, liver, 
kidneys and tumor) were collected and acquired with same 
imaging system. The scale bar was expressed as Average 
Radiant Efficiency [p/s/cm2/sr] / [μW/cm2] which is a 
calibrated measurement of photon emission.
Statistical analysis
Data are expressed as means ± SD of three 
independent experiments. Statistical analysis was done 
with a paired sample t-test. Differences were considered 
significant when p ≤ 0.05.
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